Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review
Cancers · 21.12.2023 · 16 (1) · 56
DOI: 10.3390/cancers16010056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.12.2023. Verfasst von Antonino Pantaleo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, 70013 Bari, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Italian Ministry of Health.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. While population-wide screening recommendations for PDAC in asymptomatic individuals are not achievable due to its relatively low incidence, pancreatic cancer surveillance programs are recommended for patients with germline causative variants in PDAC susceptibility genes or a strong family history. In this study, we sought to determine the prevalence and significance of germline alterations in major genes (ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53) involved in PDAC susceptibility. We performed a systematic review of PubMed publications reporting germline variants identified in these genes in PDAC patients. Overall, the retrieved articles included 1493 PDAC patients. A high proportion of these patients (n = 1225/1493, 82%) were found to harbor alterations in genes (ATM, BRCA1, BRCA2, PALB2) involved in the homologous recombination repair (HRR) pathway. Specifically, the remaining PDAC patients were reported to carry alterations in genes playing a role in other cancer pathways (CDKN2A, STK11, TP53; n = 181/1493, 12.1%) or in the mismatch repair (MMR) pathway (MLH1, MSH2, MSH6, PMS2; n = 87/1493, 5.8%). Our findings highlight the importance of germline genetic characterization in PDAC patients for better personalized targeted therapies, clinical management, and surveillance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Genetics, National Institute of Gastroenterology-IRCCS "Saverio de Bellis" Research Hospital, 70013 Bari, Italy.
- Medical Genetics, Department of Precision and Regenerative Medicine and Jonic Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy.
ORCID-Profile: Antonino Pantaleo, Candida Fasano
Förderung
- Italian Association for Cancer Research
- Italian Ministry of Health
Zitieren
APA
Pantaleo, A., Forte, G., Fasano, C., Lepore Signorile, M., Sanese, P., De Marco, K., Di Nicola, E., Latrofa, M., Grossi, V., Disciglio, V., & Simone, C. (2023). Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review. Cancers, 16(1), 56. https://doi.org/10.3390/cancers16010056
Vancouver
Pantaleo A, Forte G, Fasano C, Lepore Signorile M, Sanese P, De Marco K, et al. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review. Cancers. 2023;16(1):56. doi:10.3390/cancers16010056
BibTeX
@article{Pantaleo2023,
author = {Pantaleo, Antonino and Forte, Giovanna and Fasano, Candida and Lepore Signorile, Martina and Sanese, Paola and De Marco, Katia and Di Nicola, Elisabetta and Latrofa, Marialaura and Grossi, Valentina and Disciglio, Vittoria and Simone, Cristiano},
title = {Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {56},
doi = {10.3390/cancers16010056}
}
EUVIMED